Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis.

ABSTRACT:

Importance

Therapeutic options for patients with secondary progressive multiple sclerosis (SPMS) are limited.

Objective

To analyze disability progression in patients with SPMS treated with rituximab compared with matched control patients never treated with rituximab.

Design, setting, and participants

This retrospective cohort study analyzed data obtained from patients with SPMS at 3 multiple sclerosis centers located in Basel and Lugano, Switzerland, and Amsterdam, the Netherlands, from 2004 to 2017. Patients were included for analysis if they had received a diagnosis of SPMS, were treated (57 eligible; 54 included) or never treated (504 eligible; 59 included) with rituximab, and had at least 1 follow-up visit. The variables used for propensity score matching were sex

SUBMITTER: Naegelin Y 

PROVIDER: S-EPMC6439730 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature